Close Menu

NEW YORK — Sienna Cancer Diagnostics said on Wednesday that it has signed an exclusive distribution agreement for its hTERT test for bladder cancer in New Zealand with Scientle Innovations.

Sienna's in vitro diagnostic is designed to detect the hTERT component of telomerase, a biomarker that aids in the diagnosis of bladder cancer alongside standard urine cytology testing.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.